riabni.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: | ||
Meta Tags
| Title | Rituxan® Biosimilar | RIABNI™ |
| Description | Discover RIABNI™ as a rituximab biosimilar treatment option. See Prescribing Info & Important Safety Info including Boxed |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 54.148.237.9 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
riabni.com Valuation
|
US$13,651,723
Last updated: 2023-05-10 00:33:21
riabni.com has Semrush global rank of 775,309. riabni.com has an estimated worth of US$ 13,651,723, based on its estimated Ads revenue. riabni.com receives approximately 1,575,199 unique visitors each day. Its web server is located in United States, with IP address 54.148.237.9. According to SiteAdvisor, riabni.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$13,651,723 |
| Daily Ads Revenue | US$12,602 |
| Monthly Ads Revenue | US$378,048 |
| Yearly Ads Revenue | US$4,536,573 |
| Daily Unique Visitors | 105,014 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| riabni.com. | A | 299 | IP: 54.148.237.9 |
| riabni.com. | A | 299 | IP: 54.201.250.38 |
| riabni.com. | NS | 86400 | NS Record: ns-1339.awsdns-39.org. |
| riabni.com. | NS | 86400 | NS Record: ns-1737.awsdns-25.co.uk. |
| riabni.com. | NS | 86400 | NS Record: ns-194.awsdns-24.com. |
| riabni.com. | NS | 86400 | NS Record: ns-759.awsdns-30.net. |
HtmlToTextCheckTime:2023-05-10 00:33:21
| COVID-19: Amgen is committed to keeping our patients, customers, staff, and their families safe. Click here for more information. INDICATIONS Non-Hodgkin’s Lymphoma (NHL) RIABNI ® (rituximab-arrx) is indicated for the treatment of adult patients with: RIABNI ® (rituximab-arrx) is indicated for the treatment of adult ... Read more patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent. .. Read more Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, |
HTTP Headers
HTTP/1.1 403 Forbidden Server: awselb/2.0 Date: Mon, 01 Nov 2021 20:08:59 GMT Content-Type: text/html Content-Length: 118 Connection: keep-alive |
riabni.com Whois Information
Domain Name: RIABNI.COM Registry Domain ID: 2327977426_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2020-11-03T18:49:29Z Creation Date: 2018-10-31T14:19:24Z Registry Expiry Date: 2022-10-31T14:19:24Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS-1339.AWSDNS-39.ORG Name Server: NS-1737.AWSDNS-25.CO.UK Name Server: NS-194.AWSDNS-24.COM Name Server: NS-759.AWSDNS-30.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-20T04:41:07Z <<< |